Showing 91-100 of 4005 results for "".
SHTG: Decoding the Latest Clinical Trial Outcomes
https://reachmd.com/programs/cme/shtg-decoding-the-latest-clinical-trial-outcomes/33225/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.Targeting the Fc Receptor Pathway to Treat Red Blood Cell Alloimmunization
https://reachmd.com/programs/cme/targeting-the-fc-receptor-pathway-to-treat-red-blood-cell-alloimmunization/13908/Delve deeper into the basic biology and functions of the FcRn receptor. Could it be the key to solving the clinical conundrum of HDFN?Remnant Cholesterol: The Missing Link in ASCVD risk
https://reachmd.com/programs/cme/remnant-cholesterol-the-missing-link-in-ascvd-risk/33226/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.Targeting Mixed Hyperlipidemia with APOC3 Inhibition
https://reachmd.com/programs/cme/targeting-mixed-hyperlipidemia-with-apoc3-inhibition/33227/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.SHTG: Defining the Unmet Clinical Need
https://reachmd.com/programs/cme/shtg-defining-the-unmet-clinical-need/33224/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
https://reachmd.com/programs/cme/setting-the-bar-guideline-recommended-treatment-in-hypertriglyceridemia/33221/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.APOC3 Inhibition: A Novel Approach to Lowering TGs
https://reachmd.com/programs/cme/apoc3-inhibition-a-novel-approach-to-lowering-tgs/33222/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.Seltorexant vs Quetiapine XR in MDD With Insomnia: A 26-Week Phase 3 Comparison
https://reachmd.com/clinical-practice/psychiatry-and-mental-health/seltorexant-vs-quetiapine-xr-in-mdd-with-insomnia-a-26-week-phase-3-comparison/37644/Compare efficacy, safety, and tolerability of adjunctive seltorexant versus quetiapine XR in MDD patients with insomnia symptoms.The Adolescent Male Health Visit
https://reachmd.com/programs/clinicians-roundtable/the-adolescent-male-health-visit/955/Dr. Arik Marcell of Johns Hopkins University discusses how best to guide and counsel the adolescent male during a health care visit.Stool Transplant: The Ultimate Probiotic
https://reachmd.com/programs/gi-insights/stool-transplant-the-ultimate-probiotic/4180/The micro-organism Clostridium difficile, or C. diff, can cause serious infection and is often resistant to antibiotic therapy. A less traditional approach to treatment — the stool transplant — has emerged as a very successful therapy for patients suffering from C. diff. What does the procedure invo